BMS’ P-III (CheckMate -8HW) Study of Opdivo (nivolumab) + Yervoy (ipilimumab) for MSI-H/dMMR mCRC Attains Primary Endpoint
Shots:
- The company’s P-III (CheckMate -8HW) study met the dual 1EP of PFS in the Opdivo + Yervoy vs CT for the 1L treatment while it continues to evaluate the second dual 1EP of PFS for Opdivo + Yervoy vs Opdivo monotx. for all lines of therapy along with 2EPs incl. OS
- The safety profile of Opdivo + Yervoy combination remained consistent and manageable, with no new safety signals identified, aligning with previously reported data
- The P-III (CheckMate -8HW) study compares Opdivo + Yervoy and Opdivo monotx. or investigator's choice CT in patients with MSI-H/dMMR metastatic colorectal cancer (mCRC)
Ref: BMS | Image: BMS
Related News:- BMS’ Abecma (idecabtagene vicleucel) Receives sNDA Approval as Early Lines of Therapy for R/R Multiple Myeloma (RRMM) in Japan
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
